Competitive Landscape Of Leading Blood Glucose Monitoring And Continuous Glucose Monitoring Devices

Table of Contents

Chapter 1. Competitive Landscape of Leading Blood Glucose Monitoring (BGM) and Continuous Glucose Monitoring (CGM) Devices: Methodology and Scope
                   1.1. Research Scope
                        1.1.1. Objectives
                        1.1.2. Approach
                   1.2. Data Collection Methodology
                        1.2.1. Primary Research Model
                        1.2.2. Secondary Research Model
                   1.3. Competitive Landscape Evaluation
                        1.3.1. Competitor Profiling
                        1.3.2. Product and Technology Assessment
                   1.4. Data Validation
                   1.5. List of Primary Sources
                   1.6. List of Secondary Sources
Chapter 2. Competitive Landscape of Leading Blood Glucose Monitoring (BGM) and Continuous Glucose Monitoring (CGM) Devices
                   2.1. Recent Developments & Impact Analysis, By Key Market Participants
                   2.2. Company/Competition Categorization
                   2.3. Company Market Share Analysis
                        2.3.1. Company Market Share Analysis (BGM Devices), 2023
                        2.3.2. Company Market Share Analysis (CGM Devices), 2023
                   2.4. Company Market Position Analysis
                        2.4.1. Company Market Position Analysis, (BGM Devices) 2023
                        2.4.2. Company Market Position Analysis, (CGM Devices) 2023
                   2.5. Product Portfolio Analysis of the Key Players
                        2.5.1. Thermo Fisher Scientific (Patheon)
                        2.5.2. Abbott
                        2.5.3. Medtronic plc
                        2.5.4. F. Hoffmann-La Roche Ltd
                        2.5.5. Ascensia Diabetes Care Holdings AG
                        2.5.6. Dexcom, Inc.
                        2.5.7. Sanofi
                        2.5.8. Novo Nordisk
                        2.5.9. Insulet Corporation
                        2.5.10. Ypsomed Holdings
                        2.5.11. Glysens Incorporated
                        2.5.12. Dexcom, Inc.
                        2.5.13. Senseonics Holdings, Inc.
                        2.5.14. A. Menarini Diagnostics S.r.l.
                        2.5.15. Signos, Inc.
                   2.6. Financial Analysis: Revenue Mapping of Key Players
                   2.7. Strategy Mapping
                        2.7.1. Product Launch
                        2.7.2. Regulatory Approval
                        2.7.3. Mergers and Acquisitions
                        2.7.4. Partnerships and Collaborations
                        2.7.5. Expansion
                        2.7.6. Awards & Achievements
                        2.7.7. Others
Chapter 3. Market Conclusion
                   3.1. Analyst Perspective
                   3.2. KOL’s Insights